Enliven Therapeutics (Nasdaq: ELVN) details Q2 loss and $895M cash
Rhea-AI Filing Summary
Enliven Therapeutics, Inc. reported financial results for the second quarter ended June 30, 2026 and provided a business update. The company highlighted positive Phase 1 data for ELVN-001 in chronic myeloid leukemia, with a 61% overall major molecular response and 48% achieving major molecular response by 24 weeks at the 80 mg once-daily dose. Earlier-line patients showed 67% overall major molecular response and 55% by 24 weeks. As of the March 10, 2026 cutoff, 161 patients had been enrolled with a median treatment duration of 35 weeks and a favorable safety and tolerability profile.
Following an End-of-Phase 1 FDA meeting, 80 mg once daily was selected as the recommended Phase 3 dose for the planned ENABLE-2 second-line and later trial in CML patients previously treated with one or more TKIs, comparing ELVN-001 to physician’s choice of ATP-competitive TKI. ELVN-001 received Fast Track Designation, and ENABLE-2 is expected to start in the second half of 2026, with further Phase 3 design details to be finalized after a planned End-of-Phase 2 meeting anticipated in the third quarter of 2026.
Enliven reported a strong cash position, with $895.2 million in cash, cash equivalents and marketable securities as of June 30, 2026, expected to provide cash runway into 2030. Second-quarter 2026 research and development expenses were $29.0 million versus $21.5 million a year earlier, and general and administrative expenses were $8.2 million versus $7.1 million. Net loss for the quarter was $32.5 million, compared with $25.3 million in the second quarter of 2025, or $0.49 per share in both periods.
Positive
- None.
Negative
- None.
8-K Event Classification
Key Figures
Key Terms
Fast Track Designation regulatory
End-of-Phase 1 meeting regulatory
major molecular response medical
tyrosine kinase inhibitors medical
BCR:ABL1 gene fusion medical
Earnings Snapshot
Cash, cash equivalents and marketable securities of $895.2 million are expected to provide cash runway into 2030.
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
What were Enliven Therapeutics' Q2 2026 financial results (ELVN)?
How much cash does Enliven Therapeutics (ELVN) have and what is its runway?
What clinical data did Enliven (ELVN) report for ELVN-001 in CML?
What are Enliven Therapeutics' plans for the ENABLE-2 Phase 3 trial (ELVN)?
What regulatory milestones has ELVN-001 achieved for Enliven (ELVN)?
How did Enliven's operating expenses change year over year in Q2 2026 (ELVN)?
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): |
(Exact name of registrant as specified in its charter)
(State or other jurisdiction |
(Commission File Number) |
(IRS Employer |
||
|
|
|
|
|
|
||||
|
||||
(Address of principal executive offices) |
|
(Zip Code) |
||
Registrant’s telephone number, including area code: |
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
Securities registered pursuant to Section 12(b) of the Act:
|
|
Trading |
|
|
|
|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02 Results of Operations and Financial Condition.
On August 5, 2026, Enliven Therapeutics, Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended June 30, 2026. The full text of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.
All of the information furnished in this Item 2.02 and Item 9.01 (including Exhibit 99.1) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, and shall not be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits
Exhibit Number |
|
Exhibit Description |
99.1 |
|
Press Release issued on August 5, 2026 |
104 |
|
Cover Page Interactive Data File (embedded within the Inline XBRL document) |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
|
Enliven Therapeutics, Inc. |
|
|
|
|
Date: |
August 5, 2026 |
By: |
/s/ Richard Fair |
|
|
Name: |
Richard Fair |
|
|
Title: |
President and Chief Executive Officer |
Exhibit 99.1
Enliven Therapeutics Reports Second Quarter Financial Results and Provides a Business Update
Announced positive Phase 1 clinical data for ELVN-001 in CML, demonstrating encouraging ELVN-001 efficacy data and a favorable safety and tolerability profile
Reached alignment with the FDA on key Phase 3 trial design components
Strong balance sheet with $895 million in cash, cash equivalents and marketable securities, which is expected to provide cash runway into 2030
BURLINGAME, Calif., Aug. 5, 2026 /PRNewswire/ -- Enliven Therapeutics, Inc. (Enliven or the Company) (Nasdaq: ELVN), a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics, today reported financial results for the second quarter ended June 30, 2026, and provided a business update.
“The second quarter was an important period for Enliven as we announced compelling updated clinical data for ELVN-001, reached alignment with the FDA on key components of the ENABLE-2 Phase 3 2L+ trial design, and significantly strengthened our balance sheet,” said Rick Fair, Chief Executive Officer of Enliven. “The updated Phase 1 data support ELVN-001’s potential to become a best-in-class treatment for patients living with CML. Combined with our recent regulatory and financial progress, we are well positioned to initiate ENABLE-2 later this year and rapidly advance ELVN-001 across all lines of CML therapy.”
ELVN-001 Program Highlights
ELVN-001 is a potent, highly selective, potentially best-in-class small molecule kinase inhibitor designed to specifically target the BCR::ABL1 gene fusion, the oncogenic driver for patients living with chronic myeloid leukemia (CML).
Second Quarter 2026 Financial Results
About Enliven Therapeutics
Enliven is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics to help people not only live longer, but live better. Enliven aims to address existing and emerging unmet needs with a precision medicine approach that improves survival and enhances overall well-being. Enliven's discovery process combines deep insights into clinically validated biological targets and differentiated chemistry to design potentially first-in-class or best-in-class therapies. Enliven is based in Burlingame, California. To learn more, visit www.enliventherapeutics.com and connect with us on LinkedIn and X.
Forward-Looking Statements
This press release contains forward-looking statements (including within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended) concerning Enliven and other matters that involve substantial risks and uncertainties. These statements may discuss goals, intentions and expectations as to future plans, trends, events, results of operations and financial condition, or otherwise, based on current beliefs of Enliven's management, as well as assumptions made by, and information currently available to, Enliven's management. Forward-looking statements generally include statements that are predictive in nature and depend upon or refer to future events or conditions, and include words such as "may," "will," "should," "would," "expect," "anticipate," "plan," "likely," "believe," "estimate," "project," "intend," and other similar expressions or the negative or plural of these words, or other similar expressions that are predictions or indicate future events or prospects, although not all forward-looking statements contain these words. Statements that are not historical facts are forward-looking statements. Forward-looking statements in this press release include, but are not limited to: statements regarding the potential profile, safety, tolerability,
Page 2
efficacy and potential best-in-class profile of ELVN-001; the interpretation of data from the ongoing ENABLE trial and regulatory milestones supporting the advancement of ELVN-001 into the planned ENABLE-2 Phase 3 trial, and the timing of such advancement; the continued conduct, design, objectives, endpoints, and future clinical evaluation of ELVN-001, including the planned ENABLE-2 Phase 3 trial, the potential timing of initiation of ENABLE-2; the potential timing for advancing ELVN-001 across all lines of CML therapy; the potential timing and outcome of further FDA discussions and the finalization of additional Phase 3 trial design details, including a planned End-of-Phase 2 meeting and the timing of such meeting; Enliven’s expected cash runway; and statements by Enliven's Chief Executive Officer. Forward-looking statements are based on current beliefs and assumptions that are subject to risks and uncertainties and are not guarantees of future performance. Actual results could differ materially from those contained in any forward-looking statement as a result of various risks and uncertainties, including, without limitation, the potential for interim, topline and preliminary results from Enliven's clinical trials to materially change as additional patient data become available or following more comprehensive review; the potential for results from the ongoing or any future clinical trial of ELVN-001 to differ from the results of earlier trials of ELVN-001; ELVN-001 failing to demonstrate sufficient safety, efficacy, tolerability, durability, differentiated attributes or therapeutic benefit in current or future clinical trials; risks associated with unexpected events during the remainder of the ENABLE trial including serious adverse events, toxicities, dose reductions, discontinuations or other undesirable side effects; delays or difficulties in recruiting, enrolling or maintaining patients in ELVN-001 clinical trials; the risks of delays in completing the ongoing ENABLE trial or initiating ENABLE-2; Enliven failing to complete the ongoing ENABLE trial, to present additional data, to initiate ENABLE-2 or to advance ELVN-001 through clinical development; regulatory authorities disagreeing with Enliven's clinical trial design, dose selection, endpoints or interpretation of data, or requiring additional studies or diagnostics; developments relating to Enliven's competitors and industry which may affect the development or potential market opportunity for ELVN-001; and the potential inability of Enliven to obtain regulatory approval for, or ultimately commercialize or license, ELVN-001 or other product candidates; Enliven’s ability to obtain or maintain the benefits associated with Fast Track designation; Enliven's limited resources; the ability to attract, hire, and retain highly skilled executive officers and employees; the ability of Enliven to protect its intellectual property and proprietary technologies; the scope of any patent protection Enliven obtains or the loss of any of Enliven's patent protection; reliance on third parties, including medical institutions, contract manufacturing organizations, contract research organizations and strategic partners; geo-political developments, general market or macroeconomic conditions; Enliven's ability to obtain additional capital to fund Enliven's general corporate activities and to fund Enliven's research and development; and other risks and uncertainties more fully described in Enliven's filings with the Securities and Exchange Commission (SEC), including under the heading "Risk Factors" in Enliven's Annual and Quarterly Reports on Form 10-K and Form 10-Q filed with the SEC and in Enliven's future SEC filings. Except as required by applicable law, Enliven undertakes no obligation to revise or update any forward-looking statement, or to make any other forward-looking statements, whether as a result of new information, future events or otherwise.
This press release contains hyperlinks to information that is not deemed to be incorporated by reference into this press release.
Contact
Investors, ir@enliventherapeutics.com; Media, media@enliventherapeutics.com
Page 3
Enliven Therapeutics, Inc.
Selected Condensed Consolidated Financial Information
(in thousands, except per share data)
(unaudited)
Statements of Operations |
|
|
Three Months Ended June 30, |
|
|
Six Months Ended June 30, |
|
||||||||||
|
|
|
2026 |
|
|
2025 |
|
|
2026 |
|
|
2025 |
|
||||
Operating expenses: |
|
|
|
|
|
|
|
|
|
|
|
|
|
||||
Research and development |
|
|
$ |
28,996 |
|
|
$ |
21,491 |
|
|
$ |
49,683 |
|
|
$ |
46,386 |
|
General and administrative |
|
|
|
8,213 |
|
|
|
7,093 |
|
|
|
15,349 |
|
|
|
13,891 |
|
Total operating expenses |
|
|
|
37,209 |
|
|
|
28,584 |
|
|
|
65,032 |
|
|
|
60,277 |
|
Loss from operations |
|
|
|
(37,209 |
) |
|
|
(28,584 |
) |
|
|
(65,032 |
) |
|
|
(60,277 |
) |
Other income (expense), net |
|
|
|
4,724 |
|
|
|
3,249 |
|
|
|
8,920 |
|
|
|
6,398 |
|
Net loss |
|
|
$ |
(32,485 |
) |
|
$ |
(25,335 |
) |
|
$ |
(56,112 |
) |
|
$ |
(53,879 |
) |
Net loss per share, basic and diluted |
|
|
$ |
(0.49 |
) |
|
$ |
(0.49 |
) |
|
$ |
(0.87 |
) |
|
$ |
(1.05 |
) |
Weighted-average shares outstanding, |
|
|
|
66,172 |
|
|
|
52,105 |
|
|
|
64,495 |
|
|
|
51,084 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||
Balance Sheets |
|
|
|
|
|
|
June 30, |
|
|
December 31, |
|
||||||
|
|
|
|
|
|
|
2026 |
|
|
2025 |
|
||||||
Assets |
|
|
|
|
|
|
|
|
|
|
|
||||||
Current assets: |
|
|
|
|
|
|
|
|
|
|
|
||||||
Cash, cash equivalents and marketable securities |
|
|
|
|
|
|
$ |
895,155 |
|
|
$ |
462,621 |
|
||||
Prepaid expenses and other current assets |
|
|
|
|
|
|
|
12,184 |
|
|
|
12,257 |
|
||||
Total current assets |
|
|
|
|
|
|
|
907,339 |
|
|
|
474,878 |
|
||||
Property and equipment, net |
|
|
|
|
|
|
|
140 |
|
|
|
34 |
|
||||
Operating lease right-of-use assets |
|
|
|
|
|
|
|
1,502 |
|
|
|
383 |
|
||||
Deferred offering costs |
|
|
|
|
|
|
|
— |
|
|
|
217 |
|
||||
Other long-term assets |
|
|
|
|
|
|
|
1,242 |
|
|
|
656 |
|
||||
Total assets |
|
|
|
|
|
|
$ |
910,223 |
|
|
$ |
476,168 |
|
||||
Liabilities and Stockholders' Equity |
|
|
|
|
|
|
|
|
|
|
|
||||||
Current liabilities: |
|
|
|
|
|
|
|
|
|
|
|
||||||
Accounts payable |
|
|
|
|
|
|
$ |
371 |
|
|
$ |
2,159 |
|
||||
Accrued expenses and other current liabilities |
|
|
|
|
|
|
|
13,790 |
|
|
|
14,409 |
|
||||
Total current liabilities |
|
|
|
|
|
|
|
14,161 |
|
|
|
16,568 |
|
||||
Long-term liabilities |
|
|
|
|
|
|
|
913 |
|
|
|
— |
|
||||
Total liabilities |
|
|
|
|
|
|
|
15,074 |
|
|
|
16,568 |
|
||||
Stockholders' equity |
|
|
|
|
|
|
|
895,149 |
|
|
|
459,600 |
|
||||
Total liabilities and stockholders' equity |
|
|
|
|
|
|
$ |
910,223 |
|
|
$ |
476,168 |
|
||||
Page 4